B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

August 2016 | 39 pages | ID: BD0B79B0236EN
La Merie Publishing

Abstracts

B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

The highly restricted expression of B-cell maturation antigen (BCMA) to plasma cells and its role in the survival and growth for multiple myeloma cells makes BCMA a good potential target for enhanced immunotherapeutic strategies. This report describes and analyzes the

• Scientific rationale for BCMA-targeted therapies;
• Preclinical proof-of-concept of BCMA blockade;
• Clinical experience with BCMA-targeted therapies;
• The competitive landscape of BCMA-targeted treatment modalities;
• Profiles of anti-BCMA CAR T-cells, antibody-drug conjugate and T-cell redirecting bispecific antibodies:
• Profiles of companies involved in develompent of anti-BCMA therapy candidates.

Especially activity-enhanced antibodies and cells such as antibody-drug conjugates (ADCs) and T-cell redirecting bispecific antibodies as well as chimeric antigen receptor (CAR) T-cells, respectively, will benefit from the high target selectivity of BCMA to avoid on-target, off-tumor toxicity. As a consequence, novel cellular and humoral BCMA-targeted treatment modalities have emerged and resulting product candidates entered first-in-human clinical evaluation. Further development candidates are undergoing IND-enabling studies.

Contents

1 Target Background

2 Target Antigen Expression Profile

3 Preclinical Proof-of-Concept

4 Clinical Indications & Treatment Options

5 Clinical Experience with BCMA-Targeted Treatment Modalities

6 Treatment Modalities & Competitive Landscape

7 Drug & Cell Therapy Candidate Profiles

7.1 CAR T-Cells
7.2 Antibody-Drug Conjugate (ADC)
7.3 T-Cell Redirecting Antibodies

8 Company Profiles

9 References